Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.

RoslinCT, a UK-based contract development and manufacturing organisation specialised in advanced cell therapies, has secured an undisclosed sum from GHO Capital Partners. The company was spun out of Roslin Institute in 2006 before the institute became a part of University of Edinburgh two years later. It does not appear to have declared any other equity financing. In November 2021, RoslinCT filed a voluntary resolution to wind up the business but it is unclear whether this means GHO’s investment was for a majority stake.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).